*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
The biotechnology industry, like virtually all other global businesses, is trying to cope with the dismal economic environment. For biotech companies to survive and thrive they must have access to regular sources of funding. Otherwise, R&D efforts and commercialization activities will be severely curtailed or might even come to a halt. But what do they do when money is so tight and formerly reliable investors are now reluctant to provide financial support?
During this week's podcast, James Greenwood reveals what BIO companies are telling him about how the economy is impacting their operations and discusses what all this augurs for new drug development. Vertex Pharmaceuticals' Dr. Josua Boger provides insights on the economy from the perspective of one of the leading biopharmaceutical firms.
Greenwood and Dr. Boger also look at President Obama's 100 days in office and offer their views on the president as a supporter of biotech. They talk about presidential decisions that have impressed them and describe what additional steps they would you like to see him take to revitalize life science research.
Greenwood delineates BIO's legislative priorities for 2009 and Dr. Boger, who is retiring from his CEO position at Vertex in May, offers some words of wisdom regarding what it takes to run and ultimately succeed as a biotech company.
Joshua Boger, Ph.D., Founder and CEO, Vertex Pharmaceuticals, and Chairman, Board of Directors, Biotechnology Industry Organization (BIO)
James Greenwood, President and CEO, BIO